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skim@sgul.ac.ukAbstractAnosmin-1, encoded by the KAL1 gene, is an extracellular matrix (ECM)-associated protein
which plays essential roles in the establishment of olfactory and GNRH neurons during early
brain development. Loss-of-function mutations of KAL1 results in Kallmann syndrome with
delayed puberty and anosmia. There is, however, little comprehension of its role in the
developed brain. As reactivation of developmental signal pathways often takes part in
tumorigenesis, we investigated if anosmin-1-mediated cellular mechanisms associated with
brain tumors. Our meta-analysis of gene expression profiles of patients’ samples and public
microarray datasets indicated that KAL1 mRNA was significantly upregulated in high-grade
primary brain tumors compared with the normal brain and low-grade tumors. The tumor-
promoting capacity of anosmin-1 was demonstrated in the glioblastoma cell lines, where
anosmin-1 enhanced cell motility and proliferation. Notably, anosmin-1 formed a part of
active b1 integrin complex, inducing downstream signaling pathways. ShRNA-mediated
knockdown of anosmin-1 attenuated motility and growth of tumor cells and induced
apoptosis. Anosmin-1 may also enhance the invasion of tumor cells within the ECM by
modulating cell adhesion and activating extracellular proteases. In a mouse xenograft
model, anosmin-1-expressing tumors grew faster, indicating the role of anosmin-1 in tumor
microenvironment in vivo. Combined, these data suggest that anosmin-1 can facilitate
tumor cell proliferation, migration, invasion, and survival. Therefore, although the
normal function of anosmin-1 is required in the proper development of GNRH neurons,
overexpression of anosmin-1 in the developed brain may be an underlying mechanism
for some brain tumors.Key Words
" anosmin-1
" Kallmann syndrome
" brain tumor
" integrins
" matrix metalloproteinases
" meta-analysis
" tumor microenvironmenticen
.0 UEndocrine-Related Cancer
(2014) 21, 85–99sed under a Creative Commons
nported License.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research C T Choy, H Kim et al. Anosmin-1 promotes brain
tumors
21 :1 86IntroductionThe extracellular matrix (ECM) is fundamentally involved
in brain development, regulating the proliferation and
migration of neuronal precursors, axonal guidance, and
synapse formation. The ECM also plays a critical role
during neoplastic transformation. Anosmin-1 is a secreted
ECM-associated protein encoded by the KAL1 gene.
Loss-of-function mutations of KAL1 underlie Kallmann
syndrome (KS), a developmental disorder characterized
by the association of hypogonadotrophic hypogonadism
and anosmia. KS is caused by the defective migration of
the gonadotrophin-releasing hormone (GNRH) neurons
along the olfactory axonal pathways during early fore-
brain development (Schwanzel-Fukuda et al. 1989). KS is
a form of secondary hypogonadism due to the insufficient
hypothalamic secretion of GNRH, resulting in low plasma-
luteinizing hormone and follicle-stimulating hormone
(Hoffman & Crowley 1982).
We and others have shown that anosmin-1 is a
guidance cue (Cariboni et al. 2004) and a chemo-attractant
for the GNRH neurons (Hu et al. 2009). In human
embryonic GNRH neuroblasts, anosmin-1 induces neurite
outgrowth and cell migration through fibroblast growth
factor receptor 1 (FGFR1) pathways (Gonzalez-Martinez
et al. 2004). Anosmin-1 directly binds to FGFR1 and
modulates its signaling (Hu et al. 2009), and mutations of
FGFR1 and its ligand FGF8 have been found in KS
(Falardeau et al. 2008). Anosmin-1 also binds to urokinase
plasminogen activator (uPA), enhancing its proteolytic
activity in vitro and induces uPA-dependent cell prolifer-
ation (Hu et al. 2004). Anosmin-1 contains evolutionarily
conserved fibronectin type III (FNIII) domains (Choy &
Kim 2010) which may interact with multiple signaling
complexes on the cell surface. Both FGF/FGFR and
uPA/uPAR complexes interact with integrins (Wei et al.
1996, Mori et al. 2008). Targeted knockout of b1 integrin
impaired GNRH neuronal migration in mouse, resulting in
delayed puberty and reproductive dysfunctions (Parkash
et al. 2012), suggesting an important role of b1 integrin in
GNRH ontogeny. However, whether anosmin-1 regulates
integrin function is unknown. Integrin plays major roles
in tumorigenesis (Maglott et al. 2006, Brown et al. 2008),
mediating anchorage-independent cell growth and survi-
val. Detachment from the ECM causes a programed cell
death, termed anoikis.
Although much research has focused on the role of
anosmin-1 during development, there is little evidence for
the function of anosmin-1 in the developed brain.
According to the NCBI AceView Tissue Expression data,http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
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Printed in Great Britainanosmin-1 is expressed in various normal and pathologic
tissues, including the brain, reproductive systems, and
neuroendocrine tumors. Reactivation of developmental
programs in the adult often associates with pathological
conditions (Thiery et al. 2009), and the gene expression
profiles of tumors possess a considerable resemblance
to embryonic stem cells (Ben-Porath et al. 2008). We
hypothesized that anosmin-1-mediated signal pathways
might contribute to brain tumorigenesis. To system-
atically address this idea, we examined the KAL1 gene
expression in brain tumor microarray datasets from Gene
Expression Omnibus (GEO) and our own patients’
samples. These revealed that KAL1 was differentially
expressed according to the grade and type of tumor,
showing an upregulation in high-grade primary brain
tumors. We also found that anosmin-1 enhanced prolifer-
ation and motility of glioblastoma cells in vitro, formed a
complex with integrin b1 inducing downstream signaling,
and modulated cell adhesion. Knockdown of KAL1
decreased tumor cell motility and proliferation, but
increased apoptosis. Moreover, anosmin-1 increased the
extracellular protease activities, supporting its role in
tumor invasion. Finally, anosmin-1-expressing tumors
exhibited more aggressive behavior in vivo. These data
demonstrate novel functions of anosmin-1 in tumor
microenvironment, suggesting a common signal pathway
involved in GNRH system and brain tumorigenesis.Subjects and methods
Meta-analysis of public microarray data
We used the rank-product method, which ranks the ratio
of expression levels and tests the significance which is a
product of the corresponding ranks. Normal (N), low (L),
and high (H) groups were analysed in pairs (NL, LH, NH) to
identify differentially expressed genes. Suppose the case
with NL comparison and let Xi,j,k be the logarithm taken
the ith probe expression of jth sample in the kth group
(iZ1,.,p,jZ1,.,n,k2N,L,H). Then we can compute the
ratio of the ith probe between the expressions of the jth
sample in the low group and the lth sample in normal
group, Yi,mZXi,j,N–Xi,l,LmZ{1,.,M(ZnN!nL)}, where nN
and nL are the total number of samples in normal and low
groups respectively. After ranking the Yi,m among
M comparisons, the rank-product statistic RPi of the ith
probe can be computed by RPiZ
QM
mZ1
Ri;m
 1=M
where Ri,m isPublished by Bioscientifica Ltd.
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21 :1 87the rank of Yi,m. In order to generate the null distribution
for our hypothesis, the samples are randomly permuted
for each probe. The permuted rank-product statistics
RPi
* is computed in the same way as RPi. The empirical
P values of RPi can be obtained by
P valueiZ
PNp
rZ1
IðRPi;r!RPiÞ
Np
(Np, total permutations which is 5000; RPi
*, permuted
rank-product statistics; I(C) is 1 if C is true or zero
otherwise.) If the ith probe is higher in low group than
normal group, its rank-product statistic tends to be small
with the empirical P value close to zero, rejecting the
null hypothesis.Brain tumor biopsy sample analysis
The tissue samples were collected from consenting
patients undergoing surgery for brain tumors at
St George’s Hospital, as part of the eTUMOUR project
http://solaria.uab.es/eTumour/ (Julia-Sape et al. 2012).
Microarray analysis was performed on Affymetrix
HG-U133 Plus 2.0 chips from snap–frozen tissues. For
qRT-PCR, RNA was extracted from the formalin-fixed
paraffin-embedded (FFPE) tissues using RNeasy FFPE kit
(Qiagen). cDNAs were amplified using the Light-Cycler
plus SYBR green (Roche) in Light-Cycler 2.0 (Supple-
mentary Table 1, see section on supplementary data given
at the end of this article).Table 1 Meta-analysis of public microarray data. Microarray
samples (total 461) from GEO database used in the meta-
analyses
Group
GEO series
ID
Number and types of selected
samples
Normal brain
(53)
GSE12649 34 (adult postmortem brain)
GSE5389 11 (adult postmortem brain)
GSE5390 8 (adult postmortem brain)
Low grade
tumor (32)
GSE12907 21 (grade I astrocytoma, pilocytic)
GSE3185 3 (grade I and II astrocytoma)
GSE4780 5 (grade I and II meningioma)Cell culture
LN229 (CRL-2611), A172 (CRL-1620), and U87MG
(HTB-14) were purchased from American Type Culture
Collection (ATCC, Manassass, VA, USA) in December
2007. ATCC routinely authenticates these lines by
isoenzyme (interspecies) and STR (intraspecies) analysis.
All experiments were performed at passages!25–30. Cells
were cultured in DMEM, supplemented with antibiotics
and 5–10% FBS, at 37 8C with 5% CO2. Cells were
transfected with Fugene (Roche) and selected using
2 mg/ml puromycin or 400 mg/ml G418 (Sigma).
GSE8692 3 (oligodendroglioma, mixed
glioma)
High grade
tumor (376)
GSE4271 100 (grade III and IV astrocytoma)
GSE13041 191 (glioblastoma multiforme)
GSE4412 85 (glioblastoma multiforme,
anaplastic astrocytoma,
anaplastic mixed oligo-
astrocytoma, anaplastic
oligodendro-glioma)Recombinant anosmin-1 protein generation
The human KAL1 coding sequence was cloned into
pCEP-Pu at XbaI/BamHI sites, producing pHis-KAL. The
N-terminal 6!His-tagged anosmin-1 protein was gene-
rated in 293-EBNA cells, stably transfected with pHis-KAL,http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
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Printed in Great Britaincultured in DMEM/F12 (1:1) supplemented with
250 mg/ml G418 and 1 mg/ml puromycin. Cell surface-
associated anosmin-1 (Supplementary Figure 1, see
section on supplementary data given at the end of this
article) was extracted and purified as described by Carafoli
et al. (2008).Motility assay
Nondirectional motility was measured by live time-lapse
imaging using an Olympus IX70 inverted microscope
(Hamamatsu C4742–95, Hamamatsu, Japan) at 37 8C in
5% CO2. The images captured every 15 min were analyzed
using ImagePro Plus (Media Cybernetics, Bethesda, MD,
USA). The serum-starved cells were incubated with various
treatments for 18 h, and cell movements were recorded for
further 20 h. The cells were treated with 5% fetal bovine
serum (FBS), 50 mM amiloride, 25 mM SU5402, anti-uPA or
anti-FGFR1 ectodomain antibodies, and nonspecific
mouse IgG (Santa Cruz Biotechnology) at 10 mg/ml. Focal
adhesion kinase inhibitor II (PF-228) (Calbiochem, Darm-
stadt, Germany) was used at 5–20 mM. All inhibitors and
vehicle control (DMSO) were added 30 min before
anosmin-1 treatment.Adhesion assay
Human plasma fibronectin (5 mg/ml) or poly-L-lysine
(0.1 mg/ml)-coated culture plates were blocked with 1%
BSA. Cells resuspended in Hank’s buffered solutionPublished by Bioscientifica Ltd.
Table 2 Meta-analysis of public microarray data. Differentially expressed (DE) probes at 0.001 significance level in the three
meta-analyses
Tests
No. of significant DE probes
[alternative hypothesis]
Total no. of DE probes
(genes)
Percentage of DE probes
(DE probes/total probes)
Normal vs low (NL) 3213 [N!L] 3257 [NOL] 6470 (4864) 33.5% (Z6470/19 273)
Low vs high (LH) 3008 [L!H] 2124 [LOH] 5132 (4034) 26.6% (Z5132/19 273)
Normal vs high (NH) 4706 [N!H] 3560 [NOH] 8266 (6072) 42.8% (Z8266/19 273)
The alternative hypothesis is shown in brackets.
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21 :1 88containing 2 mM Ca2C/Mg2C were left to adhere for 1 h.
The attached cells were stained with 0.25% crystal violet
and the absorbance measured at 595 nm.Immunofluorescence and BrdU assay
Cells labelled with BrdU for 2 h were fixed and immuno-
fluorescence was performed with anti-BrdU antibody
(Millipore, Temecula, CA, USA) using Axiovert 200M
fluorescence microscope (Zeiss, Go¨ttingen, Germany). The
cells were treated with SU5402 (10 mM), amiloride (25 mM),
and recombinant anosmin-1 (20 nM). For the colocalization
study, active form of integrin b1 was detected by 12G10
antibody (Millipore) and Alexa Fluor 568 (Molecular Probes,
Eugene, OR, USA); EGFP-fused anosmin-1 was detected at
488 nm using an LSM 510 confocal microscope (Zeiss, Jena,
Germany). Images were analysed using Zen 2009 Software
and ImageJ plugin Wright Cell Imaging Facility.Cell proliferation assay
Serum-starved cells were treated with 10 nM recombinant
anosmin-1 and the number of viable cells was assessed
using CellTitre-Glo Luminescent Cell Viability kit
(Promega) following the manufacturer’s protocol.KAL1 shRNA
Sequence-verified shRNAs against human KAL1 (TRCN
#73673-73677, Sigma–Aldrich) or nontargeting (non-
mammalian) shRNA in pLKO.1-puro lentiviral vectorTable 3 Meta-analysis of public microarray data. Statistics of KAL
Tests Rank-pro
Normal vs low (NL) 2637.756 (P!0
Low vs high (LH) 3992.405 (P!0
Normal vs high (NH) 2375.587 (P!0
The lower the rank-product value is, the more significantly different the KAL1
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
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Printed in Great Britainwere produced in 293FT packaging cells. A172 cells
infected with the viral supernatant were selected in
1 mg/ml puromycin.Apoptosis assays
Caspase3/7 activity was assessed using the Caspase-Glo kit
(Promega) according to the manufacturer’s protocol.
To assess the PARP cleavage in western blots, full length
PARP was detected by anti-PARP antibody (BD Biosciences,
Oxford, UK).Western blot and coimmunoprecipitation
Total cell lysate in Triton lysis buffer containing protease/
phosphatase inhibitors was analyzed by SDS–PAGE using
antibodies against FAK, p-FAK, AKT, p-AKT, ERK, and
p-ERK (Cell Signaling, Danvers, MA, USA). Anti-anosmin-1
antibodies were mouse (Novus Biologicals, Littleton, CO,
USA) and rabbit polyclonal (LS Biosciences, Seattle, WA,
USA). The densitometry values were obtained using
Quantity One Software (Bio-Rad). For coimmunoprecipi-
tation, total cell lysates precipitated with anti-b1 integrin
(Abcam, Cambridge, UK) or nonspecific IgG (Santa Cruz)
were probed using anti-His (Qiagen), anti-GFP (Santa
Cruz), or anti-b1 (Cell Signaling) antibodies.Zymography
Total cell lysates (0.3% Triton X-100, 50 nM Tris–HCl pH
8.0, 150 nM NaCl with protease inhibitors) and the condi-
tioned medium were collected from serum-starved cells.1 in three meta-analyses
duct statistic (empirical P value) [alternative hypothesis]
.01) [N!L] 9955.508 (PZ0.993) [NOL]
.01) [L!H] 5779.429 (PZ0.072) [LOH]
.01) [N!H] 12 815.553 (PZ1.000) [NOH]
expression is in each test. Alternative hypothesis is shown in brackets.
Published by Bioscientifica Ltd.
Table 4 Analysis of 42 brain tumor cases from St George’s Hospital
Sample ID Sex Age
KAL1 level by
microarray KAL1 level by qRT-PCR Type of tumor
524 M 34 9.57 7.17!10K4 Glioblastoma (WHO grade IV)
427 M 59 11.79 2.98!10K4 Glioblastoma (WHO grade IV)
433 F 70 11.88 1.77!10K4 Glioblastoma (WHO grade IV)
409 M 57 11.13 2.67!10K5 Glioblastoma (WHO grade IV)
426 F 61 10.97 8.31!10K5 Glioblastoma (WHO grade IV)
417 M 56 11.48 4.87!10K5 Glioblastoma (WHO grade IV)
463 F 65 9.88 4.15!10K5 Glioblastoma (WHO grade IV)
018 M 79 10.14 NA Glioblastoma (WHO grade IV)
461 M 16 11.26 NA Glioblastoma (WHO grade IV)
369 F 65 10.42 NA Glioblastoma (WHO grade IV)
460 F 58 9.62 NA Glioblastoma (WHO grade IV)
366 M 40 9.96 3.23!10K4 Anaplastic ependyoma (WHO grade III)
140 F 27 11.08 NA Anaplastic astrocytoma (WHO grade III)
079 F 40 12.50 NA Astrocytoma (WHO grade II)
403 M 19 10.28 NA Gemistocytic astrocytoma (WHO grade II)
360 M 49 3.94 7.73!10K5 Meningioma (WHO grade I)
501 F 71 8.95 7.72!10K5 Meningioma (WHO grade I)
549 F 66 6.55 5.96!10K5 Meningioma (WHO grade I)
048 F 78 5.73 3.39!10K5 Meningioma (WHO grade I)
521 F 88 7.77 3.28!10K5 Meningioma (WHO grade I)
514 F 46 7.56 2.74!10K5 Meningioma (WHO grade I)
169 M 66 8.00 1.90!10K5 Meningioma (WHO grade I)
167 F 35 6.99 9.98!10K6 Meningioma (WHO grade I)
456 M 52 7.08 4.14!10K6 Meningioma (WHO grade I)
384 M 49 5.35 3.89!10K6 Meningioma (WHO grade I)
476 F 65 7.57 0 (non-detected) Meningioma (WHO grade I)
455 F 60 8.89 NA Meningioma (WHO grade I)
367 F 37 3.92 NA Meningioma (WHO grade I)
394 F 62 7.23 NA Meningioma (WHO grade I)
502 M 72 3.18 NA Meningioma (WHO grade I)
075 M 20 11.34 NA Pilocytic astrocytoma (WHO grade I)
537 F 71 6.76 2.64!10K5 Haemangioblastoma (WHO grade I)
449 M 70 6.10 2.68!10K4 Metastatic adenocarcinoma
408 M 67 4.66 4.64!10K5 Metastatic adenocarcinoma
210 F 69 7.91 1.44!10K5 Metastatic adenocarcinoma
153 F 58 9.91 4.20!10K5 Metastatic adenocarcinoma
536 M 73 5.33 1.43!10K5 Metastatic adenocarcinoma
166 F 56 6.14 NA Metastatic adenocarcinoma
475 M 60 8.13 NA Metastatic adenocarcinoma
398 F 73 8.78 NA Metastatic adenocarcinoma
211 F 65 9.22 NA Metastatic adenocarcinoma
438 M 61 6.99 NA Metastatic large cell carcinoma
The patients, types of tumors, and KAL1 expression levels assessed by microarray and qRT-PCR are shown. KAL1 mRNA level determined by qRT-PCR is
indicated as the concentration ratio normalized to b-actin (shown in Fig. 1); NA, not determined due to limited tissue availability.
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21 :1 89The samples in loading buffer (10% SDS, 4% glycerol,
0.25 M Tris–HCl pH 6.8, 0.1% bromophenol blue) were
loaded on a 10% SDS–polyacrylamide gel copolymerized
with 0.1% gelatine A for MMP-2/9 assay or with 2 mg/ml
a-casein plus 15 mg/ml plasminogen (Sigma) for uPA
assay. The gels incubated in refolding buffer (50 mM
Tris–HCl pH 7.4, 100 mM NaCl, 2.5% Triton X-100) and
developing buffer (50 mM Tris–HCl pH 7.4, 10 mM
CaCl2, 0.02% NaN3) were stained with 0.1% Coomassie
Blue and destained.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
q 2014 The authors
Printed in Great BritainMouse xenografts
All experiments were inaccordance with the local approvals.
Female NOD scid gamma (NSG) mice at 6–7 weeks old were
purchased from Charles River (Kent, UK) and 3!106 cells in
PBS were injected into the flanks. Tumors were measured
using callipers and tumor volume (V) was estimated by
VZp!(length (mm))!(width (mm))2/6. The tumor
doubling time was determined from the slope of a plot
of ln(V) against time. The paraffin-embedded tumor tissuesPublished by Bioscientifica Ltd.
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21 :1 90were analyzed by hematoxylin/eosin staining or anti-Ki67
antibody (Leica Biosystems, UK).Statistical analysis
Analysis was carried out using R language and GraphPad
Prism 5 Software (La Jolla, CA, USA).8×10–4
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High grade
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Figure 1
Expression profile of KAL1 in brain tumor tissues. KAL1 mRNA levels
assessed by qRT-PCR in tumor biopsy samples grouped as low and high
grade. Expression ratios represent relative quantification normalized
to b-actin. The PCR was performed in triplicates and repeated twice.
The average of triplicate samples is shown.Results
KAL1 is differentially expressed in brain tumor
microarrays
To test the notion that anosmin-1 is involved in
tumorigenesis of the brain, we examined KAL1 expression
in different types and grades of tumors. We first
investigated publicly available microarray data by using
meta-analysis. Meta-analysis allows the integration and
analysis of heterogeneous datasets. We chose the rank-
product method, which has higher sensitivity and
selectivity than the conventional t-test based methods
(Breitling et al. 2004, Hong & Breitling 2008). The datasets
were selected based on the availability of the histological
classification submitted to GEO database (http://www.
ncbi.nlm.nih.gov/gds), and were also generated using the
Affymetrix U133A (GLP96) gene chip. The samples that
did not correspond to the histological typing recognized
in the World Health Organization (WHO) grading
categories were excluded from the analysis. These criteria
limited the sample numbers, at the time of access (October
2009), to a total of 461 samples from ten independent
studies, the smallest consisting three samples and the
largest 191. The description of tumor types and sample
numbers associated with each GEO entry is shown
(Table 1). To obtain uniformity of the data, Gene Chip
Robust Multi-array Average (GCRMA) normalization was
applied to the raw datasets. A total of 19 273 probes were
analyzed and the data were then classified into three
groups – normal brain, low-grade tumor (WHO grade I
and II) and high-grade tumor (WHO grade III and IV).
We conducted the meta-analysis on each pair of the
three groups – normal (N) vs low-grade (L); low-grade (L)
vs high-grade (H); and normal (N) vs high-grade (H) –
under the null hypothesis that the paired groups have
the same mean expression values. The results show that
33.5, 26.6, and 42.8% of the total probes are differen-
tially expressed (i.e., up- or downregulated) in NL, LH,
and NH comparison respectively (Table 2). Notably, in
all the three tests, there was a strong evidence (empirical
P valueZ0) that KAL1 is upregulated in both low- andhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
q 2014 The authors
Printed in Great Britainhigh-grade tumors compared with normal brain, and
more elevated in high-grade tumors compared with low-
grade ones (Table 3).
Next, among the 9700 probes that showed differential
expression, we focused on the 7582 (Z3087C2585C
573C1337) probes commonly found in at least two meta-
analysis tests (Supplementary Figure 2, see section on
supplementary data given at the end of this article).
We grouped these probes according to four possible
expression patterns within each test. The total 12 patterns
and the numbers of probes in each category are
shown (Supplementary Table 4). Markedly, KAL1
belonged to the group showing a pattern of N!L!H,
indicating a positive correlation of KAL1 expression with
increasing grades.Differential expression of KAL1 in tissue biopsy samples
To further verify our findings from the public data
analyses, we generated own microarray data from 42
brain tumor biopsy samples obtained at St George’s
Hospital, which are available in the ArrayExpress database
(www.ebi.ac.uk/arrayexpress) under accession number
E-MTAB-1852. The cohort included six types of tumors
(Table 4). After excluding the ten metastatic adenocarci-
nomas, the 32 primary tumors were categorized into low
(WHO grade I and II, 19 cases) and high (WHO grade III
and IV, 13 cases) group based on histopathology. An
unpaired t-test indicated that KAL1 was significantly
upregulated in high-grade tumors (PZ4.81!10K6, false
discovery rate (FDR)Z0.256) compared with low-grade
tumors. We validated these results by directly assessingPublished by Bioscientifica Ltd.
Table 5 Differential expression of KAL1 in different tissue
origin. Microarray mean expression value of KAL1 gene in each
tumor type is shown in this table
Tissue Meningioma Astrocytoma Glioblastoma
Adeno-
carcinoma
Mean (S.D.) 7.32 (1.75) 11.30 (0.85) 10.74 (0.85) 6.58 (1.79)
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21 :1 91KAL1 mRNA by qRT-PCR. Despite the difficulty of
recovering RNA from FFPE tissue samples, the results
indicated that high-grade tumors contained higher KAL1
mRNA compared with low-grade tumors (Welch’s
t-statisticZ2.21, PZ0.031) (Table 4 and Fig. 1). Thus, our
gene expression analyses of both public and private
datasets support the notion that expression of anosmin-1
correlates with high-grade brain tumors.KAL1 associates with astrocytic tumors
So far, we compared the data purely based on WHO
grading regardless of tumor tissue origin. However, in our
biopsy samples, 11 out of 13 high-grade tumors were
glioblastoma and 15 out of 19 low-grade tumors were
meningioma. Therefore, we investigated whether KAL1
expression correlates with certain tissue origin, regardless
of grades. We found a highly significant tendency between
different tumor tissue types (one-way ANOVA, PZ2.20!
10K8, FDRZ8.95!10K7) (Table 5). In Tukey–Kramer
post hoc test, we found KAL1 was significantly upregulated
in tumors of glia/astrocyte origin (e.g., glioblastoma and
astrocytoma), compared with tumors of non-glia (e.g.,
meningioma) or non-brain origin (e.g., adenocarcinoma).
Therefore, primary brain tumors of glia/astrocyte origin
tend to express high levels of KAL1 (Table 6).KAL1 expression profiles in the REMBRANDT database
We have also compared the results of KAL1 analysis
available from the REMBRANDT database of the NationalTable 6 Differential expression of KAL1 in different tissue origin a
Adenocarcinoma Astrocyt
Adenocarcinoma – 3.98 (4.4!
Astrocytoma – –
Glioblastoma – –
Meningioma – –
Each value represents the mean expression difference between two tumor type
results (P value !0.01) are in bold.
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
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Printed in Great BritainCancer Institute (http://rembrandt.nci.nih.gov, data
released on 27 July 2010). Compared with normal tissue,
KAL1 was significantly elevated in glioblastoma
(PZ0.0000) for two of the three probe-set analyses
available, and was elevated at PZ0.0392 and PZ0.0577
in same two probe-sets for astrocytoma and at PZ0.0019
and 0.0032 for all gliomas. Although REMBRANDT
database only uses a categorization for the tissue origin
and doesn’t include WHO grading system as a component
of the analysis, the overall conclusion demonstrated both
by us and the REMBRANDT is that KAL1 is elevated in
all tumors compared with nontumor samples and shows
a particular association with astrocytoma and glioblas-
toma. These findings thus support the notion that KAL1
may contribute to tumor invasion because these tumors
exhibit highly infiltrative nature.Anosmin-1 increases tumor cell motility
As our gene analyses implicated KAL1 in glioblastomas,
we decided to investigate the putative tumor-promoting
activities of anosmin-1 in vitro using three different
glioblastoma cell lines – LN229, A172, and U87MG. The
serum-starved cells were treated with recombinant
anosmin-1 and the cellular motility was traced using
time-lapse microscopy. Anosmin-1 significantly increased
cell motility by 50% in LN229, 53% in A172, and 30%
in U87MG compared with SFM control, indicating
considerable effects of anosmin-1 in multiple glioblastoma
cell lines (Fig. 2A). To confirm the specific activity of
anosmin-1, we employed lentiviral shRNAs, designated as
673, 675, and 676, in the A172 cells which express a sub-
stantial level of endogenous KAL1 (Fig. 2D and Supple-
mentary Table 3, see section on supplementary data given
at the end of this article). After stable infection of A172,
the average knockdown of KAL1 assessed by qRT-PCR was
88% for shRNA676, 84% for shRNA675, and 67% for
shRNA673, compared with nontargeting shRNA (Fig. 2F).
Western blot analyses using anti-anosmin-1 antibodies
confirmed that the reduction in mRNA correlated to thenalyzed by Tukey’s test
oma Glioblastoma Meningioma
10K4) 3.42 (5.0!10K5) K0.74 (0.633)
0.56 (0.92) K4.72 (1.6!10K5)
– K4.16 (2.0!10K6)
– –
s (column vs row). P value is shown in the bracket and only the significant
Published by Bioscientifica Ltd.
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Figure 2
Effects of anosmin-1 in tumor cell motility. (A) Serum-starved cells were
treated with either SFM (negative control), 10 nM recombinant anosmin-1,
or FBS (positive control). The average moving distance (mm) of 20 random
cells tracked over 20 h are shown. Error bars indicate S.E.M. from five
independent experiments. The P values calculated by two-way ANOVA
between the SFM and anosmin-1-treated groups in each cell line are 0.0175
(LN229), 0.0037 (A172), and 0.0399 (U87MG), where *P%0.05 or **P%0.01
is considered significant. (B) Effects of KAL1 knockdown on A172 cell
motility. The P values obtained from three independent experiments are
0.0395 (for shRNA 673), 0.0253 (for shRNA 675), and 0.0015 (for shRNA 676)
when compared with the nontargeting control shRNA. (C) As indicated,
LN229 cells were pretreated with chemical inhibitors or specific antibodies
for 30 min before addition of anosmin-1 (labeled A). Only anosmin-1
treatment alone or with nonspecific IgG resulted in a significant increase in
motility. Error bars indicate S.E.M. from three independent experiments.
(D) LN229, A172, and U87MG cells endogenously express anosmin-1, uPA,
and FGFR1 proteins at variable levels. See Supplementary Table 3 for the
mRNA levels of each gene. (E)KAL1-shRNAs significantly knocked down the
endogenous anosmin-1 protein as assessed by two different anti-anosmin-1
(mouse or rabbit polyclonal) antibodies. (F) Knockdown efficacy of each
shRNA is indicated as the percentage of the remaining KAL1 mRNA
assessed by qRT-PCR, compared with control shRNA, which was significant
(***P%0.0001) in all three shRNAs. qRT-PCR was performed in triplicates,
from four independent experiments. Error bars indicate the S.E.M.
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21 :1 92protein suppression in these cells (Fig. 2E). When the
shRNA infected cells were examined for motility, all three
shRNAs caused a significant decrease (Fig. 2B), indicating
the essential role of anosmin-1 in tumor cell motility.
We have previously shown that anosmin-1 directly
binds to FGFR1 and uPA, inducing neurite outgrowth,
neuronal migration, and proliferation (Gonzalez-Martinez
et al. 2004, Hu et al. 2009). Thus, we asked whether these
pathways are operational in tumor cells by examining the
anosmin-1-induced motility in the presence of specific
inhibitors of FGFR1 (SU5402, FGFR1 ectodomain
antibody) or uPA (amiloride, uPA antibody). Pretreat-
ments with these inhibitors abolished the effects ofhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
q 2014 The authors
Printed in Great Britainanosmin-1 (Fig. 2C), but not that of FBS (data not
shown), suggesting that anosmin-1 induces cell motility
through FGFR1- and uPA-dependent mechanisms. Of
note, FGFR1 and uPA are expressed in all three cell lines
at variable levels (Fig. 2D and Supplementary Table 3).Anosmin-1 enhances tumor cell growth
As high-mitotic index is the hallmark of malignant
tumors, we sought to assess the effects of anosmin-1 in
glioblastoma cell proliferation by two approaches. We first
performed the BrdU incorporation assay in quiescent
LN229 cells stimulated with recombinant anosmin-1.Published by Bioscientifica Ltd.
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research C T Choy, H Kim et al. Anosmin-1 promotes brain
tumors
21 :1 93There was a 49% increase in the number of cells entering
the S phase at 6 h post treatment, which was FGFR1-
and uPA-dependent, as it was significantly attenuated
by pretreatment with SU5402 or amiloride (Fig. 3A).200
A
B
C
180
160
140
120
100
80
Br
dU
 fo
ld
 in
du
ct
io
n 
(%
)
Br
dU
 fo
ld
 in
du
ct
io
n 
(%
)
Lu
m
in
es
ce
nc
e 
(R
LU
 ×1
05
)
60
40
20
0
120
100
80
60
40
20
0
120
115
LN229
LN229+A
110
105
*
**
**
*
** **
*
100
95
90
85
80
75
70
0 h 24 h 48 h
SFM A SU5402
+ A
Amiloride
+ A
DMSO FBS
Control
shRNA
shRNA 673
(61% KD)
shRNA 675
(31% KD)
shRNA 676
(92% KD)
Figure 3
Effects of anosmin-1 in tumor cell proliferation. (A) LN229 cells were
treated with anosmin-1 for 6 h with BrdU labeling during the last 2 h in
serum-free conditions. In parallel experiments, cells were pre-treated with
SU5402 or amiloride for 30 min before stimulation with anosmin-1.
Anosmin-1-treated cells (denoted as A) show increased BrdU incorporation
(**PZ0.0035) compared with the untreated or solvent (DMSO)-treated
cells. Pretreatment with SU5402 or amiloride, however, attenuated
anosmin-1-induced proliferation (**PZ0.0046 and *PZ0.0423
respectively). At least five random fields were analysed, which were
repeated four times. (B) shRNA-mediated knockdown of KAL1 results in
reduced BrdU incorporation in A172. The P values obtained from four
independent experiments are 0.0319 (for shRNA673), 0.019 (for shRNA675),
and 0.05 (for shRNA676) when compared with the control shRNA. (C) LN229
cells treated with anosmin-1 indicate significantly higher proliferation in
CellTitre-Glo luminescent assay, compared with the untreated control at
24 h (*PZ0.0103) and 48 h (**PZ0.0048) by a two-way ANOVA test.
Error bars indicate S.E.M. from five independent experiments.
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
q 2014 The authors
Printed in Great BritainIn contrast, KAL1 shRNA-infected A172 cells showed a
significant reduction in the BrdU incorporation (Fig. 3B).
The mitotic effects of anosmin-1 were also assessed
based on the number of viable cells in the culture by the
ATP quantitation. The LN229 cells cultured in the
presence of anosmin-1 showed an increased proliferation
compared with the untreated cells at 24–48 h (Fig. 3C).Anosmin-1 interacts with b1 integrin complex and
induces FAK and AKT signaling
Both FGFR1 and uPA interact with integrins (Wei et al.
1996, Mori et al. 2008) and anosmin-1 contains the
FNIII domain known to bind to integrins (Ruoslahti
1999). To test whether anosmin-1 regulates integrin
function through direct or indirect interaction, we
examined the binding of anosmin-1 with b1 integrin
that plays major roles in invasive behavior of gliomas and
is expressed in all three cell lines we studied (Maglott et al.
2006, Brown et al. 2008). As shown in Fig. 4A, anosmin-1
was present in the protein complexes precipitated by
anti-b1 antibody in KAL1-transfected cells, which was
identifiable by both N-terminal 6!His- and C-terminal
GFP-tagged anosmin-1 constructs, indicating a specific
interaction between anosmin-1 and b1, independent of
the type or location of tag.
We also conducted a subcellular colocalization
study in cells expressing GFP-tagged anosmin-1. Immuno-
fluorescence staining with 12G10 antibody, which labels
only the active form of b1, demonstrated that anosmin-1
colocalized with activated b1 with a high Manders
Overlap Coefficient. Interestingly, in the polarized
migrating cells, anosmin-1 was mainly located at the
protruding leading edge but not at the trailing end of the
cell (Fig. 4B).
We next asked whether anosmin-1 induces integrin-
mediated signal transduction. One of the earliest events
upon integrin clustering and signaling is autophosphory-
lation of FAK at Y397, which leads to the recruitment of
PI3K to focal adhesion, causing activation of AKT that
regulates integrin-mediated cell survival. Thus, we
examined the status of these molecules in LN229 cells at
varying time points after anosmin-1 treatment. The results
show that anosmin-1 induced phosphorylation of FAK
within 30 min, which peaked at around 2 h. The phos-
phorylated AKT also appeared within 30 min, gradually
increasing up to 6 h. Similarly, phosphorylation of ERK
gradually increased for up to 6 h. Notably, A172 cells
which express a substantial level of endogenous
anosmin-1 exhibited high levels of phosphorylation ofPublished by Bioscientifica Ltd.
AB
C
D
Probe:
Probe:
Lysate
– + – + – + – + – + – +
Integrin β1
115, 135 KDa
Integrin β1
115, 135 KDa
His
IP
integrin β1
IP
IgG Lysate
IP
integrin β1
IP
IgG
Integrin β1
Lysate
– +
Hoechst Anosmin-1 Active β1 Hoechst Anosmin-1
160
1.0
1.0
1.0
LN
22
9 (0
 hrs
)
LN
22
9 (0
.5 h
rs)
LN
22
9 (2
 hrs
)
LN
22
9 (6
 hrs
)
A1
72
4.3 6.1 4.1
2.3 2.9 4.3 19.3
13.9
1.0 0.6 1.9 6.8 Densitometry ratio
Densitometry ratio
Densitometry ratio
Total ERK (42/44 kDa)
Total AKT (60 kDa)
Total FAK (125 kDa)
p-AKT (60 kDa)
p-FAK (125 kDa)
p-ERK (42/44 kDa)
140
120
**
***
*
*
*
*
*****
100
80
M
ot
ilit
y 
fo
ld
 in
du
ct
io
n 
(%
)
60
40
20
0
DM
SO
5 µ
M 
PF
22
8
10
 µM
 PF
22
8
20
 µM
 PF
22
8
A +
 5 
µM
 PF
22
8
A +
 10
 µM
 PF
22
8
A +
 20
 µM
 PF
22
8
His
KA
L +
 DM
SO
His
KA
L +
 5 
µM
 PF
22
8
His
KA
L +
 10
 µM
 PF
22
8
His
KA
L +
 20
 µM
 PF
22
8
A +
 DM
SO
Merged
20 µm 50 µm
255
Ch2
0
0 Ch1 255
Colocalisation
points
Menders
overlap
coefficient
Active β1 Merged
– + – + – + – + – +
GFP
IP
integrin β1
IP
IgG Lysate
IP
integrin β1
IP
IgG
Integrin β1
Input:
Input:
His-KAL:
KAL-GFP:
His-KAL
~90 kDa
KAL-GFP
~120 kDa
Figure 4
Interaction of anosmin-1 with b1 integrin activates downstream signal
pathways. (A) Anosmin-1 co-immunoprecipitated with b1 integrin was
identified by probing with anti-His or anti-GFP antibody in LN229 cells
transfected with pHis-KAL, pKAL-GFP (C), or empty vector (K). Integrin b1
precipitated by anti-b1 antibody or nonspecific mouse IgG is shown as
positive and negative control respectively. (B) Immunofluorescence
staining of active integrin b1 (red) in LN229 cells expressing EGFP-tagged
anosmin-1 (green). Nuclei were labeled with Hoechst (blue). The
colocalization points are also shown (white). A display color-scatter plot is
shown of red intensities (Ch1) vs green intensities (Ch2), with the pixels
representing the actual color in the image and yellow indicating
colocalization. Manders Overlap Coefficient was 0.83, where 1 represents
perfect colocalization and 0 represents no colocalization (Manders et al.
1992). On the right panel, an independent image demonstrating anosmin-1
localization at the leading edge of a polarized migrating cell. Scale bar
is shown. (C) Induction of p-FAK, p-AKT, and p-ERK upon anosmin-1
treatment in serum-starved LN229 cells at the time points indicated.
A172 lysate is included as a positive control for constitutive anosmin-1
expression. The ratio of phosphorylated vs total protein determined by
densitometry is shown as fold induction compared with the control. All
western blots were repeated twice. (D) Effects of FAK inhibitor (PF-228) on
anosmin-1-induced motility. Anosmin-1 significantly increased LN229 cell
motility (*PZ0.0302 in anosmin-1 recombinant protein treated, and
*PZ0.0208 in HisKAL-transfected). The pretreatment with increasing
concentrations of PF-228, but not with the solvent (DMSO), inhibited the
effect of anosmin-1 in a dose-dependent manner. PF-228 alone reduced
the basal level motility in LN229, as similarly reported in other cancer
cell lines (Slack-Davis et al. 2007). Error bars indicate S.E.M. from four
independent experiments (**, P%0.01; ***, P%0.001).
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21 :1 94these molecules even in SFM (Fig. 4C). To confirm the
involvement of these pathways in anosmin-1 function, we
examined the effects of a FAK inhibitor PF-228 on the
anosmin-1-induced motility. It has been reported that
PF-228 inhibits FAK phosphorylation (Tyr397) and FAK-
mediated random motility in multiple cancer cell lines
(Slack-Davis et al. 2007). In LN229 cells, PF-228 reduced
the basal level of motility about 20% in SFM. Importantly,
the increasing concentration of PF-228 abolished the
anosmin-1-induced motility in a dose-dependent manner
(Fig. 4D), supporting that FAK signaling is required for
anosmin-1 function. Combined, these data demonstrate
that anosmin-1 interacts with integrins, inducing down-
stream FAK, AKT, and ERK signaling events.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
q 2014 The authors
Printed in Great BritainEffects of anosmin-1 in integrin-mediated cell adhesion
and apoptosis
The Arg-Gly-Asp (RGD) sequence motif present in FNIII
repeats of several ECM proteins including fibronectin is
known as the integrin-binding site, and peptides that
contain such motif compete with fibronectin for integrin
binding, thereby inhibiting the attachment of the cells to
a fibronectin matrix (Ruoslahti 1996). We hypothesize
that anosmin-1 which also contains multiple FNIII
domains may compete with fibronectin, modulating
integrin-mediated cell adhesion. To test this notion, we
performed a cell adhesion assay on fibronectin-coated
plates using LN229 and U87MG cells. Anosmin-1Published by Bioscientifica Ltd.
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21 :1 95expressing cells adhere significantly less to the fibronectin
surface compared with the control (Fig. 5A), suggesting
that anosmin-1 potentially alters integrin-mediated cell
adhesion on fibronectin-containing matrix.
As anosmin-1 modulates cell adhesion (Fig. 5A)
and activates prosurvival signals (Fig. 4C), we speculate
that loss of anosmin-1 may induce apoptosis. First, we
assessed caspase3/7 activity in shRNA-infected cells
after 24 h serum-starvation. All three KAL1-knockdown
lines showed significant increases in caspase3/7 activity,
in accordance with the knockdown efficiency indicating
specific effects of anosmin-1 (Fig. 5B). Then the cleavage
of poly (ADP-ribose) polymerase (PARP) was investigated
to further assess apoptosis. Compared with the controls,
KAL1-knockdown cells contained significantly reduced100
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Figure 5
Effects of anosmin-1 on cell adhesion and survival. (A) The percentage of
cells adhered to the fibronectin-coated plates after 1 h at 37 8C was
quantified and normalized to the nonspecific total adhesion on the poly-L-
lysine-coated plate. LN229 His-KAL cells show 23% reduction (**PZ0.0044)
and U87MG KAL-GFP show 21% reduction (**PZ0.0011) in cell adhesion,
compared with the empty vector control. Experiments were performed in
quintuplicate and repeated five times. Expression of the transfected
anosmin-1 constructs is confirmed by anti-His or anti-GFP antibodies.
(B) Effects of KAL1 knockdown on apoptosis. Caspase3/7 activity of A172
cells infected with shRNA was measured in relative light units and the
average fold induction from four independent experiments is shown.
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Printed in Great Britainlevels of the full-length PARP protein, suggesting
enhanced cleavage (Fig. 5D). We then asked whether
this induction of apoptosis is accompanied by reduced
phosphorylation of AKT and ERK (Fig. 5C). We observed
80% decrease in AKT phosphorylation and 70% decrease
in ERK phosphorylation by shRNA676 with 88% knock-
down of KAL1. However, KAL1-knockdown did not
show consistent reduction in FAK phosphorylation
(Fig. 2B), indicating a functional redundancy of
anosmin-1 in FAK activation at the focal adhesion
site. As A172 contains relatively high levels of endogen-
ous FAK/p-FAK compared with other GBM cell lines
such as LN229 (Liu et al. 2007), multiple pathways
leading to FAK phosphorylation might be operational
in A172.C
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As increased levels of extracellular proteases such as uPA
and matrix metalloproteinases (MMPs) have a strong
correlation with glioma cell motility and invasion
(Gladson et al. 1995, Forsyth et al. 1998), we postulated
that anosmin-1 might modulate these proteases. The
presence and activities of MMP2 and MMP9 were
previously described in LN229 cells (Yan et al. 2001,
Rorive et al. 2008, Nan et al. 2010). Thus, we conducted the
gelatin zymography on LN229 with or without KAL1
transfection. We detected both the pro- and active forms
of MMP2 but only the proform of MMP9 in the cell lysates
and conditioned medium. However, their activities were
significantly increased (three- to seven-fold) in KAL1-
transfected cells (Fig. 6A). As uPA regulates MMP activities,
we also asked whether anosmin-1 affects uPA in the
plasminogen zymography. The KAL1-transfected cells
showed three- to six-fold increase in both pro- and active
forms of uPA (Fig. 6B). Therefore, anosmin-1 increases
the proteolytic activities of MMP2/9 and uPA in glioblas-
toma cells, which may contribute to the ECM remodeling
during tumor invasion.CM
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Figure 6
Anosmin-1 induces MMP2/9 and uPA proteolytic activity. Empty vector and
pHis-KAL-transfected LN229 were subjected to gelatin zymography to
assess MMP2 and MMP9 activities (A) or plasminogen zymography to assess
uPA activity (B). Molecular sizes of respective proteins are shown in
brackets. The 125 kDa band was previously reported as the heterodimer of
proMMP9 with lipocalin (Yan et al. 2001, Rorive et al. 2008). The bands in
the plasminogen zymography were inhibited by amiloride treatment,
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
q 2014 The authors
Printed in Great BritainAnosmin-1 enhances tumor growth in mouse
xenograft model
Our in vitro data encouraged us to further investigate the
role of anosmin-1 in vivo. Therefore, we transplanted
LN229 cells with or without KAL1-overexpression into the
flanks of immunodeficient mice. Palpable tumors were
detected after 2–3 weeks. At 53–70 days post-implantation
when the tumors reached w500 mm3 in volume, they
were excised and embedded in paraffin for histological
analysis. Tumors from both groups exhibited the histo-
logical characteristics of malignant tumors such as
pleomorphic cells, necrosis, and active mitoses with high
Ki67 scores (Fig. 7C and Supplementary Table 4), but those
derived from the KAL1-transfected cells grew significantly
faster compared with the empty vector-transfected tumors
(Fig. 7A). Mean tumor doubling times were 8.12G
0.72 days for the control group and 6.11G0.98 days for
the His-KAL group (PZ0.0023). Upon autopsy of the mice,
we observed that two out of the six anosmin-1-expressing
tumors showed much prominent gross vasculature and
physical attachment to the adjacent organs (Fig. 7B).
Further histological analysis of these organs indicated theC
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confirming the specificity of the assay. Each lane was loaded with either
40 ml conditioned medium (CM) or 80 mg total cell lysates. The fold
inductions of enzyme activity are indicated in relation to the vector
transfected cells, as determined by densitometry of the respective bands in
inverted images. (C and D) The average fold induction of the relative band
intensity is shown as a graph. All experiments were repeated three times.
Error bars indicate S.E.M.
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Figure 7
Anosmin-1 promotes tumor growth in vivo. (A) Tumor volume (V) was
calculated using the formula, VZp!(length (mm))!(width (mm))2/6.
Tumor doubling time was generated from the slope of a plot of ln(V)
against time (days post transplantation). Mean tumor doubling times were
8.12G0.72 days for the control group and 6.11G0.98 days for the LN229
His-KAL group (PZ0.0023, two-tailed t-test). (B) Images of a xenograft
tumor grown in the NSG mice. This His-KAL tumor showed prominent
vasculature and attachment to the surrounding tissues. (C) Hematoxylin
and eosin (H&E) staining of the tumour tissue indicates the characteristics
of malignant glioblastoma, such as pleomorphic cells, mitoses, and areas of
necrosis, with a high Ki67 score (Supplementary Table 4) in both groups.
Infiltration of the His-KAL tumor into the liver and diaphragm is identified
by H&E staining.
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21 :1 97presence of infiltrating tumors within the liver and
diaphragm (Fig. 7C). The continued expression of the
transfected KAL1 in the His-KAL tumor tissues was
confirmed by qRT-PCR (Supplementary Figure 3, see
section on supplementary data given at the end of this
article). These results demonstrate that overexpression of
anosmin-1 may associate with the aggressive growth of
tumors in vivo.Discussion
Reappearance of an embryonic pattern of ECM has been
observed in pathological conditions in adulthood
(Ffrench-Constant et al. 1989, Coutu et al. 2011) and
aberrant expression of developmental genes results in
malignant brain tumors (Goodrich et al. 1997). Here
anosmin-1, whose function was implicated mainly in
the early migratory events of GNRH neurons in the
developing brain, is shown to be upregulated in the
primary brain tumors, while it remains at low levels
in normal brain (Tables 1, 2 and 3). The majority ofhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-13-0181
q 2014 The authors
Printed in Great Britainglioblastoma multiforme (GBM), the most fatal and
common brain tumor, is primary (de novo development),
but some GBMs develop from lower grade astrocytomas.
KAL1 expression associated with not only the grade of
tumor but also the tissue type, showing relations with
glia and astrocyte origin, but not in the metastatic
tumors of other tissue types (Tables 5 and 6). In fact,
KAL1 is reported to be downregulated in colon, lung,
and ovarian cancer compared with normal tissues (Jian
et al. 2009). It is unknown whether KAL1 is expressed in
glia or astrocytes during embryogenesis. However, glia
cells play fundamental roles in neuronal pathfinding,
thus the failed GNRH neuronal migration in KS could be
caused by the primary glial defects.
The infiltration of neoplastic cells into the surround-
ing healthy brain is the main source for recurrence and
failure of current treatment. Anosmin-1 enhanced glio-
blastoma cell motility (Fig. 2) and colocalized with the
leading edge of migrating cells (Fig. 4B) while enhancing
uPA and MMP2/9 activities (Fig. 6). It is conceivable
that anosmin-1 concentrates these proteases at thePublished by Bioscientifica Ltd.
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their infiltration. Although the xenograft models showed
evidence of invasion in the presence of anosmin-1 (Fig. 7),
the microenvironment of the brain parenchyma is
different from that of flanks, thus the effects of anosmin-1
in brain tumor invasion will need to be reconfirmed in
orthotopic models.
The 32 amino acid sequences within the first FNIII
domain of anosmin-1 was previously reported to serve as
an adhesion matrix for different neuronal and non-
neuronal cell types in vitro (Soussi-Yanicostas et al. 1998,
Bribian et al. 2008), but the molecular basis for this was not
understood. We now postulate that the differential
adhesion to anosmin-1 may depend on the repertoire
of integrins expressed on the surface of these cells.
Anosmin-1 does not contain the typical integrin recog-
nition motif, RGD. Nonetheless, numerous variations
which do not resemble RGD but are capable of binding
to different integrins have been described (Ruoslahti
1996). Although the identity of the integrin a subtypes
involved in anosmin-1 interaction is not clear, human
GBM tissues exhibit strong expression of a2b1, a5b1, and
a6b1, compared with normal brain (Gingras et al. 1995).
Furthermore, a9b1 was shown to regulate LN229 cell
proliferation and survival (Brown et al. 2008) and a5b1
antagonist inhibited adhesion and proliferation in A172
and U87MG cells (Maglott et al. 2006).
Both uPA and MMPs are upregulated in malignant
brain tumors (Gladson et al. 1995). FGFR1 is reported
to be mutated in glioblastomas (Rand et al. 2005).
Currently, it is unclear whether anosmin-1 directly binds
to integrin or involves other interactants. We showed that
anosmin-1 may protect cells from apoptosis (anoikis),
while facilitating detachment and migration. The source
of anti-apoptotic signals for the migrating GNRH neurons
during development has not been identified. Although
Gas6 and its receptor Axl signaling has been suggested
(Allen et al. 1999), Gas6/Axl is not expressed in the GNRH
neurons themselves.
In summary, the loss-of-function mutations of
anosmin-1 disrupt the normal GNRH neuronal develop-
ment, thus causing KS, but inappropriate activation of
anosmin-1-mediated signal pathways in the developed
brain is the underlying mechanism of some malignant
brain tumors.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
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